TableĀ 1

Baseline characteristics of included trials

StudyStent typeDrug-eluting balloonControlSettingClopidogrel (mts)Follow-up (mts)MACETLR
Habara et al12DESSequent pleaseUncoated balloonStable CAD36TLR, MI, deathSymptoms and stenosis >50%
PACCOCATH96% BMSPaccocath DEBUncoated balloonStable CAD/ACS160TLR, MI, stroke, deathSymptoms and/or angiographic findings
PEPCAD 2 ISRBMSSequent pleaseTaxus LiberteStable CAD/ACS3 (6 for control arm)12TLR, MI, ST, deathNA
PEPCAD DESDESSequent pleaseUncoated balloonStable CAD/ACS66TLR, MI, CV deathSymptoms and/or angiographic findings
ISAR-DESIREDESSequent pleaseTaxus Liberte, uncoated balloonStable CAD/ACS612TLR, death, MINA
  • ACS, acute coronary syndrome; BMS, bare-metal stent; CAD, coronary artery disease; CV, cardiovascular; DES, drug-eluting stent; ISR, in-stent restenosis; MACE, definition of major adverse cardiac events; MI, myocardial infarction; Mts, months; Paccocath DEB, paccocath drug-eluting balloon, paclitaxel eluting, Bayer AG, Leverkusen, Germany; Sequent please, paclitaxel eluting balloon, Bayer, Germany; SES, sirolimus eluting stents; ST, stent thrombosis; TLR, target lesion revascularisation.